Metforal

Metformin, the active ingredient in Metforal, is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Metforal is a biguanide used to improve glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: improves fasting and post‑prandial blood glucose levels. Prediabetes (impaired glucose tolerance): reduces risk of progression to overt diabetes. Polycystic ovary syndrome: may improve insulin resistance and menstrual regularity.

Metforal may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: may develop with long‑term use. - Pancreatitis: inflammation of the pancreas.

Metforal requires careful patient assessment and monitoring.

Renal function: assess eGFR before initiating and periodically thereafter. Liver disease: use with caution in patients with hepatic impairment. Cardiovascular risk: monitor for signs of lactic acidosis, especially in heart failure. Alcohol intake: avoid excessive consumption to reduce lactic acidosis risk. Pregnancy and breastfeeding: discuss potential risks with a healthcare professional. Store at ambient temperature: keep in the original container, protect from moisture.

Metforal can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure. - Cimetidine: can increase metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes.